Published in Infect Immun on October 01, 2006
An overview of anthrax infection including the recently identified form of disease in injection drug users. Intensive Care Med (2012) 2.10
A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J Exp Med (2010) 1.58
Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother (2013) 1.25
Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun (2009) 1.22
Monoclonal antibody therapies against anthrax. Toxins (Basel) (2011) 1.19
Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding. Proc Natl Acad Sci U S A (2009) 1.14
Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum. Expert Rev Vaccines (2008) 1.13
Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax. Future Microbiol (2009) 1.11
A heterologous helper T-cell epitope enhances the immunogenicity of a multiple-antigenic-peptide vaccine targeting the cryptic loop-neutralizing determinant of Bacillus anthracis protective antigen. Infect Immun (2009) 1.10
Monoclonal antibodies and toxins--a perspective on function and isotype. Toxins (Basel) (2012) 1.09
A viral nanoparticle with dual function as an anthrax antitoxin and vaccine. PLoS Pathog (2007) 1.02
Antibodies for biodefense. MAbs (2011) 1.02
Crystal structure of the engineered neutralizing antibody M18 complexed to domain 4 of the anthrax protective antigen. J Mol Biol (2009) 1.01
Analysis of the Fc gamma receptor-dependent component of neutralization measured by anthrax toxin neutralization assays. Clin Vaccine Immunol (2009) 0.99
Antibodies against anthrax: mechanisms of action and clinical applications. Toxins (Basel) (2011) 0.99
Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis. Open Microbiol J (2010) 0.98
Targeting virulence not viability in the search for future antibacterials. Br J Clin Pharmacol (2015) 0.96
Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine. J Infect Dis (2009) 0.93
Anthrax toxin-neutralizing antibody reconfigures the protective antigen heptamer into a supercomplex. Proc Natl Acad Sci U S A (2010) 0.92
Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection. PLoS One (2009) 0.92
Comparison of three anthrax toxin neutralization assays. Clin Vaccine Immunol (2010) 0.92
Recombinant anthrax toxin receptor-Fc fusion proteins produced in plants protect rabbits against inhalational anthrax. Antimicrob Agents Chemother (2010) 0.91
Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin. Bioorg Med Chem (2007) 0.89
Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action. Clin Vaccine Immunol (2012) 0.89
Neutralizing activity and protective immunity to ricin toxin conferred by B subunit (RTB)-specific Fab fragments. Toxicon (2013) 0.86
Molecular determinants for a cardiovascular collapse in anthrax. Front Biosci (Elite Ed) (2014) 0.83
An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis. Expert Opin Investig Drugs (2015) 0.80
A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein. PLoS One (2012) 0.80
Antitoxin Treatment of Inhalation Anthrax: A Systematic Review. Health Secur (2015) 0.80
Phase I study evaluating the safety and pharmacokinetics of MDX-1303, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Vaccine Immunol (2011) 0.80
Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant. J Immune Based Ther Vaccines (2007) 0.79
Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs. Toxins (Basel) (2015) 0.79
Anti-infective immunoadhesins from plants. Plant Biotechnol J (2015) 0.78
Preparation and evaluation of human-murine chimeric antibody against protective antigen of Bacillus anthracis. Int J Mol Sci (2014) 0.77
Anthrax: an update. Asian Pac J Trop Biomed (2011) 0.76
A Novel Chimeric Anti-PA Neutralizing Antibody for Postexposure Prophylaxis and Treatment of Anthrax. Sci Rep (2015) 0.76
Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med (1979) 12.22
Anthrax toxin. Annu Rev Cell Dev Biol (2003) 5.92
Field Evaluation of a Human Anthrax Vaccine. Am J Public Health Nations Health (1962) 5.44
Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J Cell Biol (2003) 3.97
Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature (2003) 2.83
Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun (2001) 2.67
Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun (1988) 2.63
Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun (1997) 2.53
Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature (1994) 2.39
Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine (2004) 2.28
Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology (1996) 2.16
Receptor palmitoylation and ubiquitination regulate anthrax toxin endocytosis. J Cell Biol (2006) 2.15
Human antibodies from transgenic animals. Nat Biotechnol (2005) 2.04
Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect Immun (1990) 1.78
Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect Immun (2004) 1.64
A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun (2005) 1.61
Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect Immun (2006) 1.59
Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect Immun (2004) 1.47
Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis. FEMS Immunol Med Microbiol (2004) 1.46
Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect Immun (2005) 1.44
In vitro correlate of immunity in an animal model of inhalational anthrax J Appl Microbiol (1999) 1.37
Effect of Bacillus anthracis lethal toxin on human peripheral blood mononuclear cells. FEBS Lett (2002) 1.36
Anthrax vaccines. Curr Top Microbiol Immunol (2002) 1.35
Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect Immun (2006) 1.35
Anthrax lethal toxin-mediated killing of human and murine dendritic cells impairs the adaptive immune response. PLoS Pathog (2005) 1.28
Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum. Clin Diagn Lab Immunol (2004) 1.21
Human monoclonal antibodies that neutralize anthrax toxin by inhibiting heptamer assembly. Hum Antibodies (2004) 1.07
Anthrax vaccine: a review. Immunol Allergy Clin North Am (2003) 0.87
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
Parallel quorum sensing systems converge to regulate virulence in Vibrio cholerae. Cell (2002) 5.12
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol (2004) 4.09
The major Vibrio cholerae autoinducer and its role in virulence factor production. Nature (2007) 3.57
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother (2010) 3.06
Type IV pilin structure and assembly: X-ray and EM analyses of Vibrio cholerae toxin-coregulated pilus and Pseudomonas aeruginosa PAK pilin. Mol Cell (2003) 2.78
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
A colonization factor links Vibrio cholerae environmental survival and human infection. Nature (2005) 2.55
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24
Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun (2006) 2.09
Evaluation of 21st-century risks of smallpox vaccination and policy options. Ann Intern Med (2003) 1.98
Antigenic targeting of the human mannose receptor induces tumor immunity. J Immunol (2007) 1.93
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res (2008) 1.92
Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine (2009) 1.85
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood (2008) 1.74
Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol (2008) 1.69
The crystal structure of AphB, a virulence gene activator from Vibrio cholerae, reveals residues that influence its response to oxygen and pH. Mol Microbiol (2012) 1.64
Use of in vivo-induced antigen technology (IVIAT) to identify genes uniquely expressed during human infection with Vibrio cholerae. Proc Natl Acad Sci U S A (2003) 1.60
Secretion of a soluble colonization factor by the TCP type 4 pilus biogenesis pathway in Vibrio cholerae. Mol Microbiol (2003) 1.57
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A (2011) 1.55
Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol (2003) 1.54
Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res (2009) 1.48
Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect Immun (2004) 1.47
Structure of Vibrio cholerae ToxT reveals a mechanism for fatty acid regulation of virulence genes. Proc Natl Acad Sci U S A (2010) 1.46
CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood (2006) 1.45
Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis (2005) 1.44
Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood (2012) 1.43
Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood (2010) 1.40
Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol (2004) 1.39
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol (2007) 1.38
Anthrax capsule vaccine protects against experimental infection. Vaccine (2004) 1.38
Anthrax biosensor, protective antigen ion channel asymmetric blockade. J Biol Chem (2005) 1.37
Characterization of Vibrio cholerae O1 El Tor biotype variant clinical isolates from Bangladesh and Haiti, including a molecular genetic analysis of virulence genes. J Clin Microbiol (2011) 1.36
Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs (2005) 1.34
Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother (2004) 1.34
Crystal structure of the Vibrio cholerae quorum-sensing regulatory protein HapR. J Bacteriol (2007) 1.32
Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. J Immunol (2010) 1.30
Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med (2014) 1.30
Mechanism of ToxT-dependent transcriptional activation at the Vibrio cholerae tcpA promoter. J Bacteriol (2002) 1.27
The major subunit of the toxin-coregulated pilus TcpA induces mucosal and systemic immunoglobulin A immune responses in patients with cholera caused by Vibrio cholerae O1 and O139. Infect Immun (2004) 1.25
Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation. J Exp Med (2013) 1.25
Induction of protective immunity by synthetic Vibrio cholerae hexasaccharide derived from V. cholerae O1 Ogawa lipopolysaccharide bound to a protein carrier. J Infect Dis (2002) 1.22
Crystal structure of the virulence gene activator AphA from Vibrio cholerae reveals it is a novel member of the winged helix transcription factor superfamily. J Biol Chem (2005) 1.21
Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res (2012) 1.20
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother (2012) 1.19
Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res (2011) 1.15
Identification of the Vibrio cholerae enterobactin receptors VctA and IrgA: IrgA is not required for virulence. Infect Immun (2002) 1.15
Integration host factor positively regulates virulence gene expression in Vibrio cholerae. J Bacteriol (2008) 1.14
Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol Prog (2005) 1.14
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature (2016) 1.13
Advances in the development of next-generation anthrax vaccines. Vaccine (2009) 1.13
Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J Immunol (2004) 1.12
TcpF is a soluble colonization factor and protective antigen secreted by El Tor and classical O1 and O139 Vibrio cholerae serogroups. Infect Immun (2005) 1.09
Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine (2009) 1.09
A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother (2010) 1.06
Protection and attachment of Vibrio cholerae mediated by the toxin-coregulated pilus in the infant mouse model. J Bacteriol (2011) 1.05
Identification of a TcpC-TcpQ outer membrane complex involved in the biogenesis of the toxin-coregulated pilus of Vibrio cholerae. J Bacteriol (2005) 1.04
Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine (2008) 1.03
Adverse events occurring after smallpox vaccination. Semin Pediatr Infect Dis (2003) 1.03
H-NS binding and repression of the ctx promoter in Vibrio cholerae. J Bacteriol (2010) 1.01
Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants. Vaccine (2003) 1.01
CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine (2004) 0.99
Transcutaneous immunization with toxin-coregulated pilin A induces protective immunity against Vibrio cholerae O1 El Tor challenge in mice. Infect Immun (2006) 0.99
The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells. Ann N Y Acad Sci (2009) 0.99
Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol (2013) 0.98
Levels of the secreted Vibrio cholerae attachment factor GbpA are modulated by quorum-sensing-induced proteolysis. J Bacteriol (2009) 0.98
Synthetic fragments of Vibrio cholerae O1 Inaba O-specific polysaccharide bound to a protein carrier are immunogenic in mice but do not induce protective antibodies. Infect Immun (2004) 0.98
A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. Sarcoma (2013) 0.98
CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Biol Blood Marrow Transplant (2010) 0.97
Membrane association and multimerization of TcpT, the cognate ATPase ortholog of the Vibrio cholerae toxin-coregulated-pilus biogenesis apparatus. J Bacteriol (2007) 0.97
Flea-borne transmission model to evaluate vaccine efficacy against naturally acquired bubonic plague. Infect Immun (2004) 0.96
The bile response repressor BreR regulates expression of the Vibrio cholerae breAB efflux system operon. J Bacteriol (2008) 0.95
A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin beta. Clin Cancer Res (2004) 0.95
Characterization of two outer membrane proteins, FlgO and FlgP, that influence vibrio cholerae motility. J Bacteriol (2009) 0.94
Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin Cancer Res (2012) 0.93
Vibrio cholerae El Tor TcpA crystal structure and mechanism for pilus-mediated microcolony formation. Mol Microbiol (2010) 0.93
Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant. Clin Vaccine Immunol (2012) 0.92
Characterization of a novel protective monoclonal antibody that recognizes an epitope common to Vibrio cholerae Ogawa and Inaba serotypes. Microbiology (2009) 0.90
Vibrio cholerae H-NS domain structure and function with respect to transcriptional repression of ToxR regulon genes reveals differences among H-NS family members. Mol Microbiol (2003) 0.89
The physical basis of type 4 pilus-mediated microcolony formation by Vibrio cholerae O1. J Struct Biol (2011) 0.89
Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action. Clin Vaccine Immunol (2012) 0.89
An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals. Vaccine (2008) 0.89
Role of FlgT in anchoring the flagellum of Vibrio cholerae. J Bacteriol (2010) 0.87
Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol (2012) 0.87
Type 4 pilus biogenesis and type II-mediated protein secretion by Vibrio cholerae occur independently of the TonB-facilitated proton motive force. J Bacteriol (2002) 0.86
Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. J Transl Med (2007) 0.86